Figure 2
![Figure 2. Summary of the overall effects of particular second kinase inhibitors on the development and regression of BCR-ABL kinase domain mutations. After treatment with second TKI, 2 patients treated with nilotinib lost baseline mutations [(M35IT) and (G250E + F317L)] but acquired new mutations [(F359V) and (T315I + Y253H)], respectively; 1 patient treated with dasatinib lost baseline mutations (E459G + M351T + G250E) and acquired a new mutation (F317L). After treatment with a third TKI, 2 patients treated with dasatinib lost baseline mutations [(F311I + E453K) and (F359V)] but acquired new mutations [(F317L) and (V299L)], respectively.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/12/10.1182_blood-2007-03-080838/4/zh80010810660002.jpeg?Expires=1724315230&Signature=TL-4t2xXADaJDQGwL-x4DAX5uDoyClMyV8l-7Gxi4-qMXqMOggtKh3CLOZie5GLtvgMoVDe~pkPqu4cvtq6kesp6dSH~EMxlbv0DtRO5lPseX7HVc4-ryglvCw9caARgo7m3nwIQZMZpyyRPySrzeI-okpWQFJ8DOYor43id-u-yCVxzpWr0K7njyKMBwjma3A-2Oz4Vu9~Xs~-YmyQVd5wQsCdwLog2Xfg29bYeV3ljS1aPbrd5DNxCzCrPFGieSjN5mwIGX7de83BP92HpyraxegSdaVRzaq6yV0WMGLZtTu33BDHCSKTRqu-2n3avRCkdwZPoxZH~CHz4nN~2tA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Summary of the overall effects of particular second kinase inhibitors on the development and regression of BCR-ABL kinase domain mutations. After treatment with second TKI, 2 patients treated with nilotinib lost baseline mutations [(M35IT) and (G250E + F317L)] but acquired new mutations [(F359V) and (T315I + Y253H)], respectively; 1 patient treated with dasatinib lost baseline mutations (E459G + M351T + G250E) and acquired a new mutation (F317L). After treatment with a third TKI, 2 patients treated with dasatinib lost baseline mutations [(F311I + E453K) and (F359V)] but acquired new mutations [(F317L) and (V299L)], respectively.
